Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
October 10, 2008
 
Industry Categories  
News by Country  
News by MSA  
Today's News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
All Press Releases for September 19, 2006 Subscribe to this News Feed    
 

UAMS Study Finds Genetic Subtypes of Myeloma, Hope for Targeted Treatments

A genetic analysis of more than 400 patients with multiple myeloma, a cancer of the bone marrow, identified seven subtypes of the disease that had a bearing on a patient’s prognosis and offered the potential for targeted treatments, reported a team of researchers from the Myeloma Institute for Research and Therapy (MIRT) in the September issue of the journal Blood.

Little Rock, AR (PRWEB) September 19, 2006 -- A genetic analysis of more than 400 patients with multiple myeloma (http://myeloma.uams.edu/), a cancer of the bone marrow, identified seven subtypes of the disease that had a bearing on a patient's prognosis and offered the potential for targeted treatments, reported a team of researchers from the Myeloma Institute for Research and Therapy (MIRT - http://myeloma.uams.edu/) in the September issue of the journal Blood.

The researchers from the Myeloma Institute, located on the campus of the University of Arkansas for Medical Sciences (UAMS - http://www.uams.edu), used gene expression profiling to analyze bone marrow plasma cells from 414 newly diagnosed myeloma patients. Of the seven genetic disease subtypes identified, four were associated with better patient outcomes following high-dose chemotherapy and a stem cell transplantation.

An article on the study, "The molecular classification of multiple myeloma," is published in the Sept. 15, 2006, issue of Blood, the journal of the American Society of Hematology. The article is available online at http://www.bloodjournal.org/.

"These results are likely to have a profound influence on the diagnosis, prognosis and treatment of multiple myeloma," said John D. Shaughnessy Jr., Ph.D., director of the Lambert Laboratory (http://lambertlab.uams.edu/)in the MIRT. "While on the surface most myelomas look alike, the power of modern molecular techniques has allowed us to identify the specific genetic switches that are altered in each disease subtype and these insights may offer entry points for new tailored therapeutic options."

The study noted that although high-dose therapy improved the prognosis for patients with multiple myeloma, individual patients' survival remains variable and unable to be accurately predicted. The researchers said the relationship between the disease subtypes and survival rates should lead to better risk stratification.

Fenghuang Zhan, M.D., Ph.D.,is the lead author of the article. Together with Shaughnessy, other authors of the article from MIRT and UAMS were:

  • Yongsheng Huang, computer scientist research associate,MIRT
  • Simona Colla, Ph.D., post doctoral fellow, MIRT
  • James P. Stewart, Ph.D., post doctoral fellow, MIRT
  • Inchiro Hanamura, M.D., Ph.D., post doctoral fellow, MIRT
  • Sushil Gupta, Ph.D., post doctoral fellow, MIRT
  • Joshua Epstein, D.Sc., professor of medicine
  • Shmuel Yaccoby, Ph.D., associate professor of medicine and physiology
  • Jeffrey Sawyer, Ph.D., professor of pathology
  • Elias Anaissie, M.D., professor of medicine
  • Klaus Hollmig, M.D., assistant professor of medicine
  • Mauricio Pineda-Roman, M.D., assistant professor of medicine
  • Guido Tricot, M.D., Ph.D., professor of medicine and pathology
  • Frits van Rhee, M.D., Ph.D., associate professor of medicine
  • Ronald Walker, M.D., assistant professor of radiology
  • Maurizio Zangari, M.D., associate professor of medicine
  • Bart Barlogie, M.D., Ph.D., director of the MIRT and a professor of medicine and pathology

About the Myeloma Institute for Research and Therapy:

The Myeloma Institute for Research and Therapy (http://myeloma.uams.edu/) is the world's largest treatment center for multiple myeloma. The Myeloma Institute is part of the University of Arkansas for Medical Sciences (http://www.uams.edu), Arkansas' only comprehensive academic health center, with five colleges, a graduate school, a medical center, five centers of excellence and a statewide network of regional centers. For more information, visit www.uams.edu.

Contact:
Andrea Peel
Myeloma Institute for Research and Therapy | University of Arkansas for Medical Sciences
501-686-8996
http://www.myeloma.uams.edu | http://www.uams.edu

###

Other Releases by this Member
OPTIONS
Printer Friendly Version
Email this story to a colleague
CONTACT INFORMATION
Andrea Peel
Myeloma Institute for Research and Therapy (MIRT) / UAMS
501-686-8996
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright